• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • INT
    • US
    • FR
Appointment of Olivier Regnard to the position of Deputy Chief Executive Officer and Chief Financial Officer

Appointment of Olivier Regnard to the position of Deputy Chief Executive Officer and Chief Financial Officer

by Zina | Oct 17, 2017 | News

Mauna Kea Technologies announced the appointment of Olivier Regnard to the position of Deputy Chief Executive Officer and Chief Financial Officer, effective immediately. Mr. Regnard brings nearly 20 years of finance, accounting and operational experience to the...
New Economic Model Shows Significant Cost Savings when using Cellvizio® to Ascertain Diagnosis of Benign Pancreatic Cysts

New Economic Model Shows Significant Cost Savings when using Cellvizio® to Ascertain Diagnosis of Benign Pancreatic Cysts

by Zina | Oct 11, 2017 | News

Study shows a 23% reduction in surgical interventions resulting in 14% reduction in clinical costs   Mauna Kea Technologies today announced the publication of a new study highlighting significant potential cost savings in a French economic model when diagnosing...
Cellvizio® Now CE Marked for Use During Robotic-Assisted Surgery

Cellvizio® Now CE Marked for Use During Robotic-Assisted Surgery

by Zina | Oct 9, 2017 | News

Mauna Kea Technologies passes another key regulatory milestone on its ambitious product roadmap, positioning Cellvizio as a key technology to enhance surgical robotics Mauna Kea Technologies today announced that it has received CE Mark for its CelioFlex™...

Mauna Kea Technologies reports H1 financial results

by Zina | Sep 21, 2017 | News

Click to read more
Mauna Kea Technologies Reports First Half 2017 Financial Results

Mauna Kea Technologies Reports First Half 2017 Financial Results

by Zina | Sep 20, 2017 | News

Results reflect strategic focus on transition to Cellvizio pay-per-use business model in the U.S. Mauna Kea Technologies will host a conference call today at 7:30 PM (CET / Paris time) / 1:30 PM (ET / New York time) to discuss the Company’s first half of 2017...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan
  • Mauna Kea Technologies and Endotherapeutics Announce Cellvizio® First Australian Orders, Advancing CellTolerance® Commercial Expansion 
  • Mauna Kea Technologies Unveils the Outlines of its Safeguard Plan to Ensure its Turnaround
  • Mauna Kea Technologies Announces Strong Advocacy from the American Foregut Society (AFS) for Broad Reimbursement Coverage from U.S. Commercial Payors for Cellvizio 
  • See Beyond the Surface: How Cellvizio® Redefines Accuracy for Detecting and Treating Cancers

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Cookies policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}